Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07463235) titled 'Safety and Potency of a High Cabergoline Dosage in Microprolactinomas' on March 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Sao Paulo General Hospital
Condition:
Prolactinoma
Prolactin Excess
Intervention:
Drug: Cabergoline
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: March 4, 2026
Target Sample Size: 70
Countries of Recruitment:
Brazil
To know more, visit https://clinicaltrials.gov/study/NCT07463235
Published by HT Digital...